Basel, Switzerland
November 5th, 2024

Vaderis Announces Acceptance of Abstract on VAD044 Proof-of-Concept Clinical Trial in Hereditary Hemorrhagic Telangiectasia for Oral Presentation at the 2024 ASH Annual Meeting

Basel, Switzerland, November 5th, 2024 – Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announces an abstract on its medicinal drug candidate VAD044 has been accepted for oral presentation at the 66th ASH Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California.

Abstract Title	Date / Time / Presenter	Session Name / Location
A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)	Sunday December 8, 2024, 12 pm Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology / Oncology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School	Session: 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes

The abstract is available online at the 66th ASH Annual Meeting and Exposition.

- Ends -

About Vaderis

Vaderis is a clinical stage biotech company developing treatments for rare and orphan diseases associated with vascular malformations. There is a significant number of debilitating and largely untreated rare diseases, such as HHT (Hereditary Haemorrhagic Telangiectasia), in which patients have overactivation of AKT triggered by upstream genetic mutations resulting in vascular overgrowth. Vaderis is developing VAD044, a daily, oral allosteric AKT inhibitor, which has been investigated in a clinical proof of concept study in HHT patients and is currently in a 12-month Open Label Extension. There are no drugs approved to treat HHT and Vaderis aims to be the first company to develop a medicine for the treatment of HHT and other diseases associated with vascular malformations.

For further information please contact:

Vaderis Therapeutics AG
Nicholas Benedict
info@vaderis.com
www.vaderis.com